<DOC>
	<DOCNO>NCT00191854</DOCNO>
	<brief_summary>The gemcitabine-paclitaxel gemcitabine-platinum combination show promise treatment MBC ; however , optimal dose schedule combination yet determine . The primary objective study compare response rate gemcitabine-paclitaxel , gemcitabine-carboplatin , gemcitabine-cisplatin combination administer biweekly schedule metastatic breast cancer .</brief_summary>
	<brief_title>Gemcitabine Combinations Metastatic Breast Cancer ( MBC ) , 1st Line</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female patient histological cytological proven diagnosis breast cancer Stage IV disease Performance Status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Scale Patients previously receive anthracycline base regimen adjuvant therapy neoadjuvant chemotherapy progress develop metastatic disease Adequate organ function Prior chemotherapy metastatic disease Previous radiation therapy allow must include whole pelvis radiation Known suspect brain metastasis . Serious concomitant disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator Concurrent administration tumor therapy , include cytotoxic chemotherapy , hormonal therapy immunotherapy ( include trastuzumab ( Herceptin ) ) Peripheral neuropathy Common Toxicity Criteria ( CTC ) Grade great 1 . History significant neurological mental disorder , include seizure dementia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>